Acadia’s ACP-104 did not meet its primary endpoint of antipsychotic efficacy in a Phase IIb Schizophrenia trial
Filed under: gpcr | Tagged: 5-HT2A, 5HT2A, Acadia, ACP-104, ACP104, agonist, Dopamine, Dopamine D2, Dopamine D3, Muscarinic, Muscarinic M1, phase II | Leave a Comment »
